DOCSLIB.ORG

Evaluating the Use of Early Hormonal Therapy in Patients with Localised Or Locally Advanced Prostate Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Evaluating the Use of Early Hormonal Therapy in Patients with Localised Or Locally Advanced Prostate Cancer Prostate Cancer and Prostatic Diseases (2005) 8, 140–151 & 2005 Nature Publishing Group All rights reserved 1365-7852/05 $30.00 www.nature.com/pcan Review Evaluating the use of early hormonal therapy in patients with localised or locally advanced prostate cancer AV Kaisary1* 1Department of Urology, Royal Free Hospital, London, UK This article evaluates the use of early hormonal therapy in patients with localised or locally advanced prostate cancer. In patients receiving radiotherapy, an overall survival benefit is proven for adjuvant goserelin (‘Zoladex’) in locally advanced disease. Adjuvant to radical prostatectomy, castration (goserelin or orchiectomy) has demonstrated an overall survival benefit in patients with lymph node metastases. Survival advantages have not yet been proven with nonsteroidal antiandrogens, but immediate or adjuvant bicalutamide (‘Casodex’) improves objective progression-free survival in patients with locally advanced disease, with certain quality-of-life advantages over castration. Prostate Cancer and Prostatic Diseases (2005) 8, 140–151. doi:10.1038/sj.pcan.4500800 Published online 26 April 2005 Keywords: prostate cancer; hormonal therapy; castration; luteinising hormone- releasing hormone agonist; nonsteroidal antiandrogen Introduction of those who undergo watchful waiting progress and require treatment initiation within 5 y,7 although among Since the onset and widespread use of prostate-specific those with low-risk, localised disease (pcT2a, low antigen (PSA) testing, an increasing proportion of Gleason score and low PSA level), this proportion may prostate cancer cases are being diagnosed at an earlier be reduced to around 20%.8 stage and in younger men.1 In the USA in 2004, an Prostate cancer progression can have a serious impact estimated 86% of prostate cancer diagnoses were for on patients’ quality of life.9,10 Advancing disease may be localised or locally advanced disease.2 associated with debilitating disease-related complications, Men with localised or locally advanced prostate cancer such as painful bone metastases and urinary tract obstru- and a life expectancy of X10 y are typically offered ction,11,12 and can cause considerable emotional distress.13 primary therapy of curative intent, that is, radical Moreover, disease progression poses a significant eco- prostatectomy, external beam radiotherapy or brachy- nomic burden.14,15 A recent large retrospective cohort therapy. However, a significant proportion of patients evaluation of US patients with prostate cancer showed undergoing these therapies experience disease progres- that healthcare resource charges were more than 50% sion (clinical and/or biochemical) and may ultimately higher among those with metastatic progression compared die from their prostate cancer.3–6 Watchful waiting with those with no evidence of progression (Po0.0001).14 (where patients receive palliative therapy only) is an In patients with locally advanced disease (pT3, N0), option for men who are not suitable for, or opt not to external beam radiotherapy as adjuvant to radical receive, primary therapy of curative intent. Around half prostatectomy has been shown to significantly improve clinical progression-free survival compared with radical prostatectomy alone (83 vs 75% at 5 y median follow-up; *Correspondence: AV Kaisary, Royal Free Hospital, Pond Street, P ¼ 0.004).16 However, both radical prostatectomy and London NW3 2QG, UK. radiotherapy target the prostatic area and neither single E-mail: [email protected] nor combined local therapies are able to eradicate distant ‘Casodex’ and ‘Zoladex’ are trademarks of the AstraZeneca group of companies. disease. Many treatment failures after local therapies are Received 10 March 2005; accepted 23 March 2005; published online 26 likely to be due to the presence of distant micrometas- April 2005 tases that were undetectable at the time of diagnosis. Early hormonal therapy in men with prostate cancer AV Kaisary The use of early hormonal therapy (ie given immedi- (HR) for overall survival (HR 1.23) indicated a non- 141 ately rather than being deferred until clinical progre- significant 23% trend in favour of early castration ssion) has been evaluated with a view to improving the therapy (Table 1). outcomes of primary therapy of curative intent and as an Turning to the nonsteroidal antiandrogens, the on- alternative to watchful waiting. As there are several going bicalutamide Early Prostate Cancer (EPC) pro- different hormonal approaches that can be considered, gramme recently demonstrated that bicalutamide physicians need to help patients weigh the potential (‘Casodex’) monotherapy significantly reduces the risk benefits of treatment (in terms of reduced risk of disease of disease progression in patients with locally advanced progression and death from prostate cancer and in- disease.20 The EPC programme is the world’s largest creased overall survival) and the potential side effects. prostate cancer treatment programme, consisting of three Only through this process can physicians be confident randomised, placebo-controlled trials conducted in dif- that their patients are able to select the approach most ferent geographical areas and involving 8113 patients. appropriate in their specific circumstances. The programme is evaluating bicalutamide given in In this article, I review findings from randomised trials addition to standard care (watchful waiting, radical examining the use of early hormonal therapy (castration prostatectomy or radiotherapy) in patients with localised therapy and/or antiandrogens) as an alternative to or locally advanced disease. A subgroup of 2285 patients watchful waiting, and as adjuvant or neoadjuvant in the programme are undergoing watchful waiting as therapy in patients receiving radical prostatectomy or standard care; among these patients, analysis at 5.4 y radiotherapy. median follow-up revealed that the relative effect of bicalutamide was dependent on disease stage (Table 1).20 In the watchful waiting patients with locally advanced disease, bicalutamide significantly reduced the risk of Effects on clinical progression and objective progression by 47% compared with watchful overall survival waiting alone (HR 0.53; Po0.0001; Figure 1).20 This does appear to be translating into a survival benefit as there Hormonal therapy alone was a trend toward improved overall survival with bicalutamide (HR 0.81; P ¼ 0.097; Figure 2). On examining the evidence, I found that there are clear In the watchful waiting patients with localised disease, benefits associated with using early hormonal therapy as the effect of bicalutamide on progression was smaller an alternative to watchful waiting in patients with locally (HR 0.81; P ¼ 0.018; Figure 1) and there was a trend advanced disease (Table 1). For this patient group, who towards reduced overall survival with bicalutamide (HR have a high chance of progression, the results from trials 1.23; P ¼ 0.05; Figure 2).20 These data suggest that, for of castration therapy17–19 or a nonsteroidal antiandro- patients with localised disease not suitable for primary gen20 indicate to me that a watchful waiting approach is therapy of curative intent because of age or comorbid- not appropriate and that hormonal therapy is best ities, watchful waiting with hormonal therapy deferred started at, or soon after, diagnosis. until signs of progression may be the best option. A significant clinical benefit in favour of early This strategy would be consistent with a recent report castration therapy was first demonstrated in a trial on the use of active surveillance for patients with low- conducted by the Medical Research Council (MRC). This risk localised disease, with selective delayed intervention trial evaluated early orchiectomy or a luteinising being initiated depending on specific disease progression hormone-releasing hormone agonist (LHRHa) vs the criteria (eg rapid PSA progression).8 The active surveil- same treatment deferred until clinical progression in lance approach offers a practical compromise between patients with either nonmetastatic (M0) disease consid- therapy of curative intent for all, which results in ered too advanced for primary therapy of curative intent overtreatment in those with indolent disease, and or asymptomatic metastatic (M1) disease. Among the watchful waiting with palliative therapy only, which subgroup of 500 patients with M0 disease, a first analysis results in undertreatment in those with aggressive (performed after 74% of the overall trial population had disease. Klotz8 conducted the first feasibility study of died; median follow-up time not reported) demonstrated the active surveillance approach in 299 patients with significant advantages for early vs deferred castration low-risk, localised disease (mostly pcT2a disease, PSA therapy in reducing progression to M1 disease (38 vs level o10 ng/ml and Gleason score p6), and concluded 59%; Po0.001) and improving overall survival (mortality that a PSA doubling time of o3 y is the optimal 59 vs 70%; P ¼ 0.02) (Table 1).17 A later analysis threshold for radical intervention, and that this included (performed after 86% of the overall trial population around 20% of patients in his series. Klotz did not had died) found that the treatment difference in overall consider the use of hormonal therapy in their study survival was no longer statistically significant (Table 1).18 design, but in light of the recent data from the EPC The reduction in this treatment difference was explained programme, one
Load more

Recommended publications
  • Quality of Life Outcomes After Brachytherapy for Early Prostate Cancer
    Prostate Cancer and Prostatic Diseases (1999) 2 Suppl 3, S19±S20 ß 1999 Stockton Press All rights reserved 1365±7852/99 $15.00 http://www.stockton-press.co.uk/pcan Quality of life outcomes after brachytherapy for early prostate cancer MS Litwin1, JM Brandeis1, CM Burnison1 and E Reiter1 1UCLA Departments of Urology, Health Services, and Radiation Oncology, UCLA, California, USA Despite the absence of empirical evidence, there is a XRT. Sildena®l appeared to have little effect in the radical popular perception that brachytherapy results in less prostatectomy patients. However, brachytherapy patients impairment of health-related quality of life. This study not receiving hormonal ablation or XRT who took silde- compared general and disease-speci®c health-related na®l had better sexual function and bother scores than quality of life in men who had undergone either brachy- those patients who did not. therapy (with and without pre-treatment XRT) or radical prostatectomy, and in healthy age-matched controls. Method Conclusion We surveyed all patients with clinical T2 or less prostate General health-related quality of life did not differ greatly cancer who had undergone interstitial seed brachyther- between the three groups, but there were variations in apy at UCLA during the previous 3±17 months. Each was disease-speci®c (urinary, bowel and sexual) health-related paired with two randomly selected, temporally matched quality of life. Radical prostatectomy patients had the radical prostatectomy patients. Healthy, age-matched worst urinary function (leakage), but brachytherapy controls were drawn from the literature. Surgery and patients were also signi®cantly worse than the controls.
    [Show full text]
  • Prostate Biopsy in the Staging of Prostate Cancer
    Prostate Cancer and Prostatic Diseases (1997) 1, 54±58 ß 1997 Stockton Press All rights reserved 1365±7852/97 $12.00 Review Prostate Biopsy in the staging of prostate cancer L Salomon, M Colombel, J-J Patard, D Gasman, D Chopin & C-C Abbou Service d'Urologie, CHU, Henri Mondor, CreÂteil, France The use of prostate biopsies was developed in parallel with progress in our knowledge of prostate cancer and the use of prostate-speci®c antigen (PSA). Prostate biopsies were initially indicated for the diagnosis of cancer, by the perineal approach under general anesthesia. Nowadays prostate biopsies are not only for diagnostic purposes but also to determine the prognosis, particularly before radical prostatectomy. They are performed in patients with elevated PSA levels, by the endorectal approach, sometimes under local anesthesia.(1±3) The gold standard is the sextant biopsy technique described by Hodge4,5, which is best to diagnose prostate cancer, particularly in case of T1c disease (patients with serum PSA elevation).6±13 Patients with a strong suspicion of prostate cancer from a negative series of biopsies can undergo a second series14;15 with transition zone biopsy16,17 or lateral biopsy.18,19 Karakiewicz et al 20 and Uzzo et al 21 proposed that the number of prostate biopsies should depend on prostate volume to improve the positivity rate. After the diagnosis of prostate cancer, initial therapy will depend on several prognostic factors. In the case of radical prostatectomy, the results of sextant biopsy provide a wealth of information.22,23 The aim of this report is to present the information given by prostate biopsy in the staging of prostate cancer.
    [Show full text]
  • The Effect of Circumcision on the Mental Health of Children: a Review •
    Turkish Journal of Psychiatry 2012 Th e Eff ect of Circumcision on the Mental Health of Children: A Review • Mesut YAVUZ1, Türkay DEMİR2, Burak DOĞANGÜN2 SUMMARY Circumcision is one of the oldest and most frequently performed surgical procedures in the world. It is thought that the beginning of the male circumcision dates back to the earliest times of history. Approximately 13.3 million boys and 2 million girls undergo circumcision each year. In western societies, circumcision is usually performed in infancy while in other parts of the world, it is performed at different developmental stages. Each year in Turkey, especially during the summer months, thousands of children undergo circumcision. The motivations for circumcision include medical-therapeutic, preventive-hygienic and cultural reasons. Numerous publications have suggested that circumcision has serious traumatic ef- fects on children’s mental health. Studies conducted in Turkey draw attention to the positive meanings attributed to the circumcision in the com- munity and emphasize that social effects limit the negative effects of circumcision. Although there are many publications in foreign literature about the mental effects of the circumcision on children’s mental health, there are only a few studies in Turkey about the mental effects of the one of the most frequently performed surgical procedures in our country. The aim of this study is to review this issue. The articles related to circumcision were searched by keywords in Pubmed, Medline, EBSCHOHost, PsycINFO, Turkish Medline, Cukurova Index Database and in Google Scholar and those appropriate for this review were used by authors. Key Words: Circumcision, child, mental health, psychology, trauma INTRODUCTION the Pacific (WHO 2006).
    [Show full text]
  • Needle Biopsy and Radical Prostatectomy Specimens David J Grignon
    Modern Pathology (2018) 31, S96–S109 S96 © 2018 USCAP, Inc All rights reserved 0893-3952/18 $32.00 Prostate cancer reporting and staging: needle biopsy and radical prostatectomy specimens David J Grignon Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, IUH Pathology Laboratory, Indianapolis, IN, USA Prostatic adenocarcinoma remains the most common cancer affecting men. A substantial majority of patients have the diagnosis made on thin needle biopsies, most often in the absence of a palpable abnormality. Treatment choices ranging from surveillance to radical prostatectomy or radiation therapy are largely driven by the pathologic findings in the biopsy specimen. The first part of this review focuses on important morphologic parameters in needle biopsy specimens that are not covered in the accompanying articles. This includes tumor quantification as well as other parameters such a extraprostatic extension, seminal vesicle invasion, perineural invasion, and lymphovascular invasion. For those men who undergo radical prostatectomy, pathologic stage and other parameters are critical in prognostication and in determining the appropriateness of adjuvant therapy. Staging parameters, including extraprostatic extension, seminal vesicle invasion, and lymph node status are discussed here. Surgical margin status is also an important parameter and definitions and reporting of this feature are detailed. Throughout the article the current reporting guidelines published by the College of American Pathologists and the International Collaboration on Cancer Reporting are highlighted. Modern Pathology (2018) 31, S96–S109; doi:10.1038/modpathol.2017.167 The morphologic aspects of prostatic adenocarcinoma hormonal therapy.4,5 For needle biopsy specimens the have a critical role in the management and prognos- data described below are largely based on standard tication of patients with prostatic adenocarcinoma.
    [Show full text]
  • Robot-Assisted Radical Prostatectomy in a Patient with a Preexisting Three-Piece Inflatable Penile Prosthesis
    www.kjurology.org DOI:10.4111/kju.2010.51.1.70 Case Report Robot-Assisted Radical Prostatectomy in a Patient with a Preexisting Three-Piece Inflatable Penile Prosthesis Kyung Hwa Choi, Seung Hwan Lee, Won Sug Jung1, Byung Ha Chung Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, 1National Health Insurance Corporation Ilsan Hospital, Goyang, Korea We report a rare case of robot-assisted laparoscopic radical prostatectomy (RARP) in Article History: a patient with a preexisting penile prosthesis. In this case, we completed RARP without received 27 August, 2009 14 October, 2009 removing the reservoir by using a deflation-inflation technique, and there were no com- accepted plications related to the prosthesis. The patient had a negative surgical margin. The Corresponding Author: preserved three-piece inflatable penile prosthesis continued to function properly in 1 Byung Ha Chung month. Reservoir-preserving RARP is technically feasible and safe. However, it is im- Department of Urology, Yonsei portant to be aware of device-related complications. Long-term studies on the mechan- University Health System, Gangnam Severance Hospital, 712, Eonju-ro, ical survival rate and patient satisfaction should be also performed. Dogok-dong, Gangnam-gu, Seoul Key Words: Robotics, Prostatectomy, Penile prosthesis, Prostatic neoplasms 135-720, Korea TEL: +82-2-2019-3474 FAX: +82-2-3462-8887 E-mail: [email protected] Prostate cancer has been reported to occur most frequently CASE REPORT in men over 40 years of age. In organ-confined cases, radical prostatectomy is the treatment of choice. After the in- 1. Patient troduction of the da VinciⓇ surgical system (Intuitive The patient was a 64-year-old male diagnosed with aci- Surgical, Sunnyvale, USA), robot-assisted laparoscopic nar-type prostate adenocarcinoma with a Gleason score of radical prostatectomy (RARP) has become a mainstay of 6 (3＋3) by prostate biopsy.
    [Show full text]
  • Eunuchs in the Bible 1. Introduction
    Acta Theologica Supplementum 7 2005 EUNUCHS IN THE BIBLE ABSTRACT In the original texts of the Bible a “eunuch” is termed saris (Hebrew, Old Testament) or eunouchos (Greek, New Testament). However, both these words could apart from meaning a castrate, also refer to an official or a commander. This study therefore exa- mines the 38 original biblical references to saris and the two references to eunouchos in order to determine their meaning in context. In addition two concepts related to eunuchdom, namely congenital eunuchs and those who voluntarily renounce marriage (celibates), are also discussed. 1. INTRODUCTION The concept of a “eunuch” (a castrate) is described in the Bible prima- rily by two words, namely saris (Hebrew, Old Testament) and eunouchos (Greek, New Testament) (Hug 1918:449-455; Horstmanshoff 2000: 101-114). In addition to “eunuch”, however, both words can also mean “official” or “commander”, while castration is sometimes indirectly referred to without using these terms. This study therefore set out to determine the true appearance of eunuchism in the Bible. The aim was to use textual context and, in particular, any circum- stantial evidence to determine which of the two meanings is applic- able in each case where the word saris (O.T.) or eunouchos (N.T.) occurs in the Bible. All instances of the words saris and eunouchos were thus identified in the original Hebrew and Greek texts of the Bible and compared with the later Septuagint and Vulgate texts, as well as with Afrikaans and English Bible translations. The meanings of the words were determined with due cognisance of textual context, relevant histo- rical customs and attitudes relating to eunuchs (Hug 1918:449-455; Grey 1974:579-85; Horstmanshoff 2000:101-14).
    [Show full text]
  • Delayed Multiple Port Sites Metastases After Laparoscopic Radical Prostatectomy
    CASE REPORT Delayed Multiple Port Sites Metastases After Laparoscopic Radical Prostatectomy Brusabhanu Nayak, MS, MCH, Prem Nath Dogra, MS, MCH, Vaibhav Saxena, MS, MCH, Ashis Saini, MS, MCH Department of Urology, All India Institute of Medical Sciences, New Delhi, India (all authors). ABSTRACT Introduction: Laparoscopic port site metastases are recurrent nodular lesions developing locally in the abdominal wall within the scar tissue of one or more trocar sites. We are reporting an extremely rare case of delayed multiple port site metastases 3 years after laparoscopic radical prostatectomy. In this case, 3 port site metastases appeared 3 years after laparoscopic radical prostatectomy. Case Description: A 65-year-old man was evaluated for lower urinary tract symptoms and found to have raised serum prostate-specific antigen of 9.06 ng/mL. Transrectal ultrasonography-guided biopsy of the prostate revealed an adeno- carcinoma of the prostate (Gleason score 3 ϩ 4 ϭ 7), with 5 of 12 cores positive for tumor. Contrast-enhanced computed tomography showed localized disease with no involvement of seminal vesicle or lymph nodes. The bone scan was normal. He underwent laparoscopic radical prostatectomy for localized carcinoma of the prostate. He developed 3 port site metastases 3 years after surgery. In view of multiple port site metastatic disease, bilateral orchiectomy was done. The patient is doing well after 1 year of follow-up. Conclusion: We report an occurrence of delayed multiple port site metastases after laparoscopic radical prostatectomy. The 3 sites of metastases in our case included the extraction site, the most active instrument site, and the drain placement site.
    [Show full text]
  • Gender Dysphoria Treatment – Commercial Medical Policy
    UnitedHealthcare® Commercial Medical Policy Gender Dysphoria Treatment Policy Number: 2021T0580J Effective Date: April 1, 2021 Instructions for Use Table of Contents Page Related Commercial Policies Coverage Rationale ....................................................................... 1 • Blepharoplasty, Blepharoptosis and Brow Ptosis Documentation Requirements ...................................................... 3 Repair Definitions ...................................................................................... 4 • Botulinum Toxins A and B Applicable Codes .......................................................................... 5 • Cosmetic and Reconstructive Procedures Description of Services ................................................................. 9 • Gonadotropin Releasing Hormone Analogs Benefit Considerations .................................................................. 9 Clinical Evidence ......................................................................... 10 • Habilitative Services and Outpatient Rehabilitation U.S. Food and Drug Administration ........................................... 15 Therapy References ................................................................................... 15 • Panniculectomy and Body Contouring Procedures Policy History/Revision Information ........................................... 16 • Rhinoplasty and Other Nasal Surgeries Instructions for Use ..................................................................... 17 Community Plan Policy • Gender Dysphoria
    [Show full text]
  • 1. Castration and Vasectomy
    CASTRATION AND VASECTOMY Castration: Indications: To render the animal docile, malignant diseases or irreparable injury to the scrotum or tactical, enlarged prostate, to improve the quality of flash, operation for scrotal hernia. Surgical Anatomy: The wall of scrotum consists of skin, Dartos (layer of connective tissue and smooth muscle) which is closely adhered to the skin, scrotal fascia, tunica vaginalis and external cremaster muscle. The testis lies in the scrotum which is covered by tunica albuginia followed by tunica vaginalis visceralis. The epididymis is attached to the dorsal border of the testis. The spermatic cord contain internal spermatic artery and vain, lymphatic, epididymis, internal spermatic plexus, ductus deference internal cremaster muscle and tunica vaginalis visceralis. Control and Anesthesia: Animal is secured in lateral recumbency with the upper hind leg pulled forward towards the shoulder region or in standing position. Sedation with Xylazine @ 0.1 mg /kg b wt followed by anterior epidural anesthesia Site: The scrotum can be incised on its lateral or posterior aspect of each testicle in case of bulls and posterior downward in case of horse. Surgical Procedure: A longitudinal skin incision is made on the posterior aspects of scrotum just lateral to median raphae. The underline muscles, tunica vaginalis and tunica albugenia are separated. Once the tunica albugenia incised testical is taken out and spermatic cord is isolated by separating from vascular portion to nonvascular portion. One artery forceps is applied on the spermatic cord and double transfixation sutures are placed one inch away from each other above the artery forceps. After placing the transfixation suture the testical is separated by cutting the spermatic cord just below the artery forceps similarly non vascular part is also legated and severed.
    [Show full text]
  • Gender Dysphoria Treatment – Community Plan Medical Policy
    UnitedHealthcare® Community Plan Medical Policy Gender Dysphoria Treatment Policy Number: CS145.I Effective Date: March 1, 2021 Instructions for Use Table of Contents Page Related Community Plan Policies Application ..................................................................................... 1 • Blepharoplasty, Blepharoptosis, and Brow Ptosis Coverage Rationale ....................................................................... 1 Repair Definitions ...................................................................................... 3 • Botulinum Toxins A and B Applicable Codes .......................................................................... 4 • Cosmetic and Reconstructive Procedures Description of Services ................................................................. 8 • Gonadotropin Releasing Hormone Analogs Benefit Considerations .................................................................. 9 Clinical Evidence ........................................................................... 9 • Panniculectomy and Body Contouring Procedures U.S. Food and Drug Administration ........................................... 14 • Rhinoplasty and Other Nasal Surgeries References ................................................................................... 14 • Speech Language Pathology Services Policy History/Revision Information ........................................... 16 Commercial Policy Instructions for Use ..................................................................... 16 • Gender Dysphoria Treatment
    [Show full text]
  • Quality of Life After Open Or Robotic Prostatectomy, Cryoablation Or
    Quality of Life After Open or Robotic Prostatectomy, Cryoablation or Brachytherapy for Localized Prostate Cancer Malcolm JB, Fabrizio MD, Barone BB, Given RW, Lance RS, Lynch DF, Davis JW, Shaves ME, Schellhammer PF Departments of Urology (JBM, MDF, BBB, RWG, RSL, DFL, JWD, PFS) and Interventional Radiology (MES), The Virginia Prostate Center at Eastern Virginia Medical School, Norfolk, VA J Urol 2010, 183: 1822 – 1829 HIGHLIGHTS • Highest urinary function and bother scores were reported with cryotherapy • Cryoablation post treatment scores exceeded 100% of baseline, presuming reduction in outlet obstruction with subsequent improvement in obstructive and irritative symptoms • Largest prospective, single center study evaluating HRQOL profiles for cryotherapy, ORP, RAP, BT BACKGROUND • Operative treatments for prostate cancer may produce comparable oncological outcomes • Patient reported quality of life outcomes – important measures – vary among options OBJECTIVE • To prospectively compare the health related QOL impact and recovery profiles for four common prostate treatment modalities METHODS • Prospective, longitudinal cohort study of HRQOL outcomes • Evaluated cryoablation, open radical prostatectomy (ORP), robotic assisted laparoscopic radical prostatectomy (RAP) or brachytherapy (BT) • Participants completed a self-administered UCLA-PCI questionnaire - Questionnaires pre treatment and 3, 6, 12, 18, 24, 30 and 36 months post treatment - HRQOL urinary, sexual and bowel function and bother scored using a 100-point scale • Baseline and
    [Show full text]
  • Robotic Surgery for Male Infertility
    Robotic Surgery for Male Infertility Annie Darves-Bornoz, MD, Evan Panken, BS, Robert E. Brannigan, MD, Joshua A. Halpern, MD, MS* KEYWORDS Robotic surgical procedures Infertility Male Vasovasostomy Varicocele KEY POINTS Robotic-assisted approaches to male infertility microsurgery have potential practical benefits including reduction of tremor, 3-dimensional visualization, and decreased need for skilled surgical assistance. Several small, retrospective studies have described robotic-assisted vasectomy reversal with com- parable clinical outcomes to the traditional microsurgical approach. Few studies have described application of the robot to varicocelectomy, testicular sperm extrac- tion, and spermatic cord denervation. The use of robotic-assistance for male infertility procedures is evolving, and adoption has been limited. Rigorous studies are needed to evaluate outcomes and cost-effectiveness. INTRODUCTION with intraperitoneal and pelvic surgery. On the other hand, many of the theoretic and practical ad- Up to 15% of couples have infertility, with approx- 1,2 vantages offered by the robotic approach are imately 50% of cases involving a male factor. A highly transferrable to surgery for male infertility: substantial proportion of men with subfertility have surgically treatable and even reversible etiologies, High quality, 3-dimensional visualization is such as a varicocele or vasal obstruction. The essential for any microsurgical procedure. introduction of the operating microscope revolu- Improved surgeon ergonomics are always desir- tionized the field of male infertility, dramatically able, particularly given the surgeon morbidity improving visualization of small, complex associated with microsurgery.3 anatomic structures. The technical precision Filtering of physiologic tremor can improve pre- afforded has improved operative outcomes across cision during technically demanding micro- the board.
    [Show full text]